The Hugo robotic surgery system [Image from Medtronic]Medtronic (NYSE:MDT) said today that it expects to submit its Hugo surgical robot to the FDA for urology indications in early 2025.

雨果机器人手术系统[美敦力图片]美敦力（纽约证券交易所：MDT）今天表示，预计将于2025年初向FDA提交雨果手术机器人用于泌尿外科适应症。

Chair and CEO Geoff Martha said on the company’s second-quarter earnings call that the medtech giant expects a submission in the first quarter of calendar year 2025.

主席兼首席执行官杰夫·玛莎（GeoffMartha）在公司第二季度盈利电话会议上表示，这家医疗科技巨头预计将在2025年第一季度提交报告。

On the call, Martha said the company is “investing in a strong foundation for future growth.” In addition to the Hugo submission, Medtronic highlighted the launch for its Touch Surgery Live Stream and fast enrollment in hernia and gynecology studies.

在电话中，玛莎表示，公司正在“为未来的增长奠定坚实的基础”。除了雨果提交的申请外，美敦力还强调了其Touch Surgery直播的推出以及疝气和妇科研究的快速注册。

“We continue to invest in our Hugo platform,” Martha said. “We’ve completed capturing the necessary data for urology submission and expect to file with the FDA in the first quarter of calendar 2025. We’re also seeing fast enrollment in our next two U.S. indication studies, hernia and gynecology.”

“我们继续投资于雨果平台，”玛莎说。“我们已经完成了获取泌尿科提交所需数据的工作，预计将在2025年第一季度向FDA提交文件。我们还看到，在接下来的两项美国适应症研究（疝气和妇科）中，注册人数也很快。”

Martha expects to bring ICG fluorescent imaging to Hugo in certain countries soon. He also anticipates adding the company’s LigaSure vessel-sealing technology to Hugo in 2025.

Martha预计很快会在某些国家将ICG荧光成像技术带给雨果。他还预计在2025年将公司的LigaSure容器密封技术添加到雨果中。

Hugo is a modular, multi-quadrant platform designed for various surgical procedures. It features wristed instruments, 3D visualization and surgical video capture options in Touch Surgery Enterprise. Medtronic first unveiled Hugo in September 2019 as a potential competitor to long-time industry leader Intuitive Surgical..

Hugo是一个模块化的多象限平台，专为各种外科手术而设计。它在Touch Surgery Enterprise中提供了精巧的器械、3D可视化和手术视频捕获选项。美敦力于2019年9月首次推出雨果，作为长期行业领导者直觉手术的潜在竞争对手。。

The company continues to build on the Hugo platform, adding more clinical studies earlier this year to expand its indications to hernia and gynecology. In August, Martha said on the company’s first-quarter earnings call that the company continued its progress on the work needed for an FDA submission Hugo..

该公司继续在Hugo平台上进行建设，今年早些时候增加了更多的临床研究，以将其适应症扩展到疝气和妇科。8月，Martha在公司第一季度盈利电话会议上表示，公司在向FDA提交Hugo所需的工作方面继续取得进展。。

“We’re absolutely committed to this … not just being a part of this, but helping to lead it, as we do in spine,” Martha said of surgical robotics.

玛莎谈到外科机器人学时说：“我们绝对致力于此……不仅是其中的一部分，而且还有助于领导它，就像我们在脊柱方面所做的那样。”。

In September, the company bolstered its surgical robotics efforts with the appointment of Dr. James Porter as chief medical officer of Robotic Surgical Technologies and Digital Technologies.

9月，该公司任命詹姆斯·波特博士为机器人手术技术和数字技术的首席医疗官，以加强其手术机器人的工作。